Sustained Release of FGF-21 from a Genetically Engineered Injectable Depot for the Treatment of Type 2 Diabetes

被引：0
|
作者：
Gilroy, Caslin A.
Chilkoti, Ashutosh
机构：
来源：
DIABETES | 2017年 / 66卷
基金：
美国国家卫生研究院;
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1092-P
引用
收藏
页码：A289 / A289
页数：1
相关论文
共 50 条
  • [21] The association of FGF-21 with the risk of newly diagnosed type-2 diabetes mellitus: a cross-sectional study in Southern China
    Lili You
    Xiaosi Hong
    Hongshi Wu
    Diefei Liang
    Feng Li
    Dinghao Zheng
    Xiuwei Zhang
    Dan Liu
    Qingyu Chen
    Li Yan
    Meng Ren
    Wei Wang
    BMC Endocrine Disorders, 23
  • [22] Long-lasting anti-diabetic efficacy of PEGylated FGF-21 and liraglutide in treatment of type 2 diabetic mice
    Ye, Xianlong
    Qi, Jianying
    Ren, Guiping
    Xu, Pengfei
    Wu, Yunzhou
    Zhu, Shenglong
    Yu, Dan
    Li, Shujie
    Wu, Qiang
    Muhi, Rasool Lubna
    Li, Deshan
    ENDOCRINE, 2015, 49 (03) : 683 - 692
  • [23] Long-lasting anti-diabetic efficacy of PEGylated FGF-21 and liraglutide in treatment of type 2 diabetic mice
    Xianlong Ye
    Jianying Qi
    Guiping Ren
    Pengfei Xu
    Yunzhou Wu
    Shenglong Zhu
    Dan Yu
    Shujie Li
    Qiang Wu
    Rasool Lubna Muhi
    Deshan Li
    Endocrine, 2015, 49 : 683 - 692
  • [24] Exenatide LAR: A sustained-release formulation of exenatide for the treatment of type 2 diabetes
    Krause, Ashley
    Kirwin, Jennifer
    FORMULARY, 2010, 45 (02) : 43 - +
  • [25] Budget Impact Analysis of Metformin Sustained Release for the Treatment of Type 2 Diabetes in The Netherlands
    Gout-Zwart, Judith J.
    de Jong, Lisa A.
    Saptenno, Lisanne
    Postma, Maarten J.
    PHARMACOECONOMICS-OPEN, 2020, 4 (02) : 321 - 330
  • [26] Budget Impact Analysis of Metformin Sustained Release for the Treatment of Type 2 Diabetes in The Netherlands
    Judith J. Gout-Zwart
    Lisa A. de Jong
    Lisanne Saptenno
    Maarten J. Postma
    PharmacoEconomics - Open, 2020, 4 : 321 - 330
  • [27] Potential of FGF21 in type 2 diabetes mellitus treatment based on untargeted metabolomics
    Li, Shuai
    Song, Zilong
    Fan, Chunxiang
    Zhang, Weiwei
    Ma, Tianyi
    Li, Xu
    Zhang, Qi
    Zhao, Ming
    Yu, Tianfei
    Li, Shanshan
    BIOCHEMICAL PHARMACOLOGY, 2024, 225
  • [28] FGF-21, Its Receptors and Target Genes in Skeletal Muscle and Adipose Tissue in Obesity and Type 2 Diabetes: Effects of Insulin and Exercise Training
    Kruse, Rikke
    Vienberg, Sara G.
    Vind, Birgitte F.
    Andersen, Birgitte
    Hojlund, Kurt
    DIABETES, 2016, 65 : A479 - A479
  • [29] The changes of plasma FGF-21 levels in type 2 diabetic mellitus, diabetic ketosis and normal subjects
    Yang, G.
    Li, L.
    Yang, M.
    He, N.
    DIABETOLOGIA, 2008, 51 : S268 - S268
  • [30] Role of Injectable Medications in Type 2 Diabetes Treatment
    Miller, Eden M.
    JOURNAL OF FAMILY PRACTICE, 2017, 66 (10): : S4 - S6
12345